BiomX (PHGE) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
25 Feb, 2026Opening remarks and agenda
The meeting was called to order by the CEO, welcoming stockholders and outlining the purpose of the special meeting.
It was announced that the required quorum had not been achieved as of the meeting date.
Overview of voting outcomes
Due to the lack of quorum, the meeting was adjourned and rescheduled to March 11, 2026, at 8:00 A.M. Eastern Time, to allow more time for proxy solicitation and voting.
The record date for voting eligibility remains February 3, 2026.
Stockholders who have already voted do not need to vote again unless they wish to change their vote.
Votes will be counted according to the most recently submitted proxy instructions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BiomX
- Approval granted for issuance of shares tied to Series Y preferred stock and warrants.PHGE
EGM 202611 Mar 2026 - 2025 net loss reached $36.2M; cash burn and insolvency drive urgent need for new financing.PHGE
Q4 202519 Feb 2026 - Approval sought for major share issuance and potential meeting adjournment to secure votes.PHGE
Proxy Filing13 Feb 2026 - Registering 5.3M shares for resale may cause major dilution as focus shifts to phage therapies.PHGE
Registration Filing9 Feb 2026 - Approval sought for major stock issuance tied to recent $3M Private Placement and governance changes.PHGE
Proxy Filing3 Feb 2026 - $50M financing boosts pipeline, but losses and delisting risk require new capital by late 2025.PHGE
Q2 20241 Feb 2026 - Phage therapy advances with two Phase II programs and major clinical milestones expected in 2025.PHGE
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - BX211 phase II fully enrolled; BX004 phase II-B delayed; Q3 net income $9.6M, cash $24.7M.PHGE
Q3 202414 Jan 2026 - BX004 and BX211 show strong clinical progress, >$12M raised, and key data readouts ahead.PHGE
Q4 2024 & Study Result25 Dec 2025